[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
OBJECTIVE
We investigated as to whether dosedependent extrapyramidal tolerance of Flupentixol decanoate is inferior to that of Risperidone.


METHODS
143 Risperidone and 177 Flupentixol decanoate treated patients were consecutively entered into this non - randomized open study and assessed with the Simpson-Angus-Scale regarding presence of rigor. Treatment comparisons of rigor frequency was done by Kaplan-Meier analysis.


RESULTS
The risk of rigor increased with dose on both treatments. EPMS-risk was not increased under treatment with Flupentixol decanoate (mean dose 35.06 +/- 19.7 mg/2 weeks) compared to Risperidone (mean daily dose: 5.2 +/- 2.5 mg/kg) when comparable weight standardized Haloperidol equivalence doses (WHE) were used.


CONCLUSIONS
This study offers limited evidence for methodological reasons. Yet, results do not support the view that EPS are more frequent on Flupentixol decanoate than on Risperidone when doses are comparable.
Scherer
Josef
J
Klinik des Bezirks Oberbayern am Klinikum Garmisch-Partenkirchen. josef.scherer@psychiatrie-gap.de
Dobmeier
Peter
P
Kuhn
Karin
K
Schmaus
Werner
W
D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D001835:Body Weight; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005475:Flupenthixol / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D009460:Neurologic Examination / Q000187:drug effects; D011446:Prospective Studies; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects*
D014150:Antipsychotic Agents; C007761:flupenthixol decanoate; D005475:Flupenthixol; D006220:Haloperidol; D018967:Risperidone